Pages
Blogroll
- Blood Pressure Risk Factors
- Electric mobility scooters
- Hair Growth Product Reviews
- Hoveround Wheelchairs
- Medical Scales
- Mortgage modification trial payments
- NBA Basketball Betting
- Nursing career
- Pancreas Cancer
- Prevent Cancer
- Prostate Cancer Treatment Side Effects
- Type 2 Diabetes Mellitus
Categories
- Cancer Risk
- Cells and Organs
- General Information
- Prostate Help Organizations
- UK Prostate Cancer
- Uncategorized
Archives
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
Meta
Press Release
FDA Approves Drug for Patients with Advanced Prostate Cancer
The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer.
Degarelix is intended to treat patients with advanced prostate cancer. It belongs to a class of agents called gonadotropin releasing hormone (GnRH) receptor inhibitors. These agents slow the growth and progression of prostate cancer by suppressing testosterone, which plays an important role in the continued growth of prostate cancer.
Hormonal treatments for prostate cancer may cause an initial surge in testosterone production before lowering testosterone levels. This initial stimulation of the hormone receptors may temporarily prompt tumor growth rather than inhibiting it. D…
Original post by Cancer Commentary and software by Elliott Back
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.